Keywords
How to Cite
Abstract
The study of individual biomedical cellular products, such as autologous vaccines, is associated with significant challenges that impose major constraints on the research methodology in oncology. Cellular therapies often generate, on one hand, heightened expectations fueled by hopes for a cure for malignant neoplasms, and on the other, skepticism regarding their efficacy due to a range of potential biases that call the reported research results into question. In this communication, as part of a discussion with our colleagues, we present our perspective on these issues using the example of the previously published article "The Autologous CaTeVac Dendritic Cell Vaccine in Patients with Melanoma: Final Results of the DENDRON-01 Study".
References
Нехаева Т.Л., Ефремова Н.А., Новик А.В., et al. Применение аутологичной дендритно-клеточной вакцины CaTeVac у больных меланомой: заключительные результаты исследования DENDRON-01. Вопросы онкологии. 2025; 71(4):00-00, # 2437.-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2437.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-The-Autologous. [Nekhaeva T.L., Efremova N.A., Novik A.V., et al. The use of the autologous CaTeVac dendritic cell vaccine in patients with melanoma: final results of the DENDRON-01 study. Voprosy Onkologii = Problems in Oncology. 2025; 71(4):00-00, # 2437.-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2437.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-The-Autologous (In Rus)].
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research (REGATA). N.N. Petrov National Medical Research Center of Oncology. Clinical Trial Record. Clinicaltrials.gov: National Library of Medicine. NCT05539677:-URL: https://www.clinicaltrials.gov/study/NCT05539677?term—REGATA&rank—1 (19.06.2024).
Новик А.В., Проценко С.А., Анохина Е.М., et al. Тридцатилетний опыт лекарственного лечения меланомы в НМИЦ онкологии им. Н.Н. Петрова: важные уроки для будущих исследований. Эффективная фармакотерапия. 2020; 16(33): 58-75. -URL: https://elibrary.ru/item.asp?edn=vriiez [Novik A.V., Protsenko S.A., Anokhina Ye.М. Thirty years experience of melanoma therapy in N.N. Petrov National Medical Research Center of Oncology: Important experience for future research. Effective Pharmacotherapy. 2020; 16(33): 58-75. -URL: https://elibrary.ru/item.asp?edn=vriiez (In Rus)].
Parums D.V. Editorial: First regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs) — Lifileucel (Amtagvi). Med Sci Monit. 2024; 30: e944927.-DOI: https://doi.org/10.12659/msm.944927.-URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11071689/pdf/medscimonit-30-e944927.pdf.
Topalian S.L., Muul L.M., Solomon D., Rosenberg S.A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987; 102(1): 127-141.-DOI: https://doi.org/10.1016/s0022-1759(87)80018-2.-URL: https://www.sciencedirect.com/science/article/abs/pii/S0022175987800182?via %3Dihub.
Lengyel A.S., Meznerics F.A., Galajda N., et al. Safety and efficacy analysis of targeted and immune combination therapy in advanced melanoma-a systematic review and network meta-analysis. Int J Mol Sci. 2024; 25(23).-DOI: https://doi.org/10.3390/ijms252312821.
Sheng F., Yan Y., Zeng B. Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis. Front Pharmacol. 2023; 14: 1284240.-DOI: https://doi.org/10.3389/fphar.2023.1284240.
Строяковский Д.Л., Абдулоева Н.Х., Демидов Л.В., et al. Меланома кожи. Клинические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли. 2025; 15(3s2): 322-354.-DOI: https://doi.org/10.18027/2224-5057-2025-15-3s2-1.2-12. [Stroyakovsky D.L., Abdulloeva N.H., Demidov L.V., et al. Cutaneous Melanoma. RUSSCO Clinical Guidelines, Part 1.2. Malignant Tumors. 2025; 15(3s2): 322-354.-DOI: https://doi.org/10.18027/2224-5057-2025-15-3s2-1.2-12 (In Rus)].
Омельяновский В.В., Агафонова Ю.А., Мухортова П.А., et al. Конечные точки и исходы в онкологических исследованиях реальной клинической практики. Вопросы онкологии. 2025; 71(4): 697-714, #OF-2305.-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2305.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-Endpoints-and-Outcomes. [Omelyanovskiy V.V., Agafonova J.A., Mukhortova P.A., et al. Endpoints and outcomes in real-world oncology clinical trials. Voprosy Onkologii = Problems in Oncology. 2025; 71(4): 697-714, # OF-2305.-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2305.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-Endpoints-and-Outcomes (In Rus)].
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2026